Header Logo

Connection

RAJYALAKSHMI LUTHRA to Leukemia, Myeloid, Acute

Back to Details
This is a "connection" page, showing publications RAJYALAKSHMI LUTHRA has written about Leukemia, Myeloid, Acute.
RAJYALAKSHMI LUTHRA
Connection Strength
1.414
Leukemia, Myeloid, Acute
  1. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud. 2021 06; 7(3).
    View in: PubMed
    Score: 0.199
  2. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73.
    View in: PubMed
    Score: 0.117
  3. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45.
    View in: PubMed
    Score: 0.106
  4. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis. J Mol Diagn. 2011 Nov; 13(6):678-86.
    View in: PubMed
    Score: 0.101
  5. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011 Jan; 135(1):35-45.
    View in: PubMed
    Score: 0.097
  6. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677.
    View in: PubMed
    Score: 0.046
  7. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689.
    View in: PubMed
    Score: 0.046
  8. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019 02; 104(2):305-311.
    View in: PubMed
    Score: 0.041
  9. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol. 2018 05; 42(5):569-577.
    View in: PubMed
    Score: 0.040
  10. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.
    View in: PubMed
    Score: 0.033
  11. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.
    View in: PubMed
    Score: 0.032
  12. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
    View in: PubMed
    Score: 0.031
  13. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8.
    View in: PubMed
    Score: 0.031
  14. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9.
    View in: PubMed
    Score: 0.030
  15. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.
    View in: PubMed
    Score: 0.030
  16. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.
    View in: PubMed
    Score: 0.029
  17. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666.
    View in: PubMed
    Score: 0.028
  18. Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. PLoS One. 2012; 7(7):e41485.
    View in: PubMed
    Score: 0.027
  19. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013 Jan; 54(1):138-44.
    View in: PubMed
    Score: 0.027
  20. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012 Oct; 25(10):1405-12.
    View in: PubMed
    Score: 0.027
  21. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22.
    View in: PubMed
    Score: 0.027
  22. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9.
    View in: PubMed
    Score: 0.027
  23. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5.
    View in: PubMed
    Score: 0.026
  24. Molecular and clinicopathologic characterization of AML with isolated trisomy 4. Am J Clin Pathol. 2012 Mar; 137(3):387-94.
    View in: PubMed
    Score: 0.026
  25. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73.
    View in: PubMed
    Score: 0.026
  26. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol. 2011 Jan; 135(1):62-9.
    View in: PubMed
    Score: 0.024
  27. Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 02; 116(23):5074-5.
    View in: PubMed
    Score: 0.024
  28. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62.
    View in: PubMed
    Score: 0.023
  29. JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome. Hum Pathol. 2010 May; 41(5):758-62.
    View in: PubMed
    Score: 0.023
  30. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol. 2009 May; 131(5):647-55.
    View in: PubMed
    Score: 0.022
  31. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol. 2008 Aug; 21(8):1029-36.
    View in: PubMed
    Score: 0.020
  32. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res. 2004 Jun; 28(6):547-50.
    View in: PubMed
    Score: 0.015
  33. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013 Dec; 88(12):1055-61.
    View in: PubMed
    Score: 0.007
  34. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.